Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection
NCT ID: NCT04327479
Last Updated: 2022-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
728 participants
OBSERVATIONAL
2020-03-26
2022-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Imaging Biomarkers Associated With Plasma ad Cellular Determinants of Cardiovascular Disease at the Time of COVID 19
NCT05745753
Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19
NCT04624503
Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity
NCT04828629
Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19)
NCT05085262
Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases
NCT04375748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Assessment of cardiovascular diseases and cardiovascular risk factors
At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Essen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tienush Rassaf, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Essen, Deparment of Cardiology and Vascular Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Essen
Essen, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mahabadi AA, Mincu R, Dykun I, Michel L, Kung A, Witzke O, Kill C, Buer J, Rassaf T, Totzeck M. Frequency and prognosis of CVD and myocardial injury in patients presenting with suspected COVID-19 - The CoV-COR registry. Int J Cardiol Heart Vasc. 2023 Apr;45:101184. doi: 10.1016/j.ijcha.2023.101184. Epub 2023 Feb 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-9213-BO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.